Penmenvy Disease Interactions
There are 2 disease interactions with Penmenvy (meningococcal group acwy conjugate-group b vaccine (cvx 328)).
Meningococcal conjugate vaccine (applies to Penmenvy) GBS
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Guillain-Barre Syndrome
Persons previously diagnosed with Guillain-Barre syndrome (GBS) may be at increased risk of GBS following receipt of meningococcal conjugate vaccine. The decision to give this vaccine should take into account the potential benefits and risks.
Vaccines (live attenuated/toxoid) (applies to Penmenvy) immunocompromised
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency
The expected antibody responses may not be obtained when live attenuated vaccines and/or toxoids are administered to immunosuppressed persons, including those receiving immunosuppressive therapy. Caution and close monitoring is advised.
Switch to professional interaction data
Penmenvy drug interactions
There are 303 drug interactions with Penmenvy (meningococcal group acwy conjugate-group b vaccine (cvx 328)).
Report options
More about Penmenvy (meningococcal group acwy conjugate-group b vaccine (cvx 328))
- Penmenvy consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- FDA approval history
- Drug class: bacterial vaccines
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.